Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

DA Haas-Kogan, MD Prados, T Tihan… - Journal of the …, 2005 - academic.oup.com
Background: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib
(also known as Tarceva or OSI-774) has shown promising response rates in malignant …
被引用次数：557 相关文章

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.

DA Haas-Kogan, MD Prados, T Tihan… - JNCI: Journal of the …, 2005 - search.ebscohost.com
Abstract < bold> Background: </bold> The epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor erlotinib (also known as Tarceva or OSI-774) has shown promising …
[PDF] academia.edu

[PDF][PDF] Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib

DA Haas-Kogan, MD Prados, T Tihan… - Journal of the National …, 2005 - academia.edu
Background: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib
(also known as Tarceva or OSI-774) has shown promising response rates in malignant …

Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib

DA Haas-Kogan, MD Prados, T Tihan… - Journal of the National …, 2005 - elibrary.ru
Background: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib
(also known as Tarceva or OSI-774) has shown promising response rates in malignant …

[引用][C] Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib

DA Haas-Kogan, MD Prados, T Tihan… - JNCI: Journal of the …, 2005 - cir.nii.ac.jp
Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib
| CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 論文・データをさがす …

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

DA Haas-Kogan, MD Prados… - Journal of the …, 2005 - pubmed.ncbi.nlm.nih.gov
Background The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib
(also known as Tarceva or OSI-774) has shown promising response rates in malignant …

[引用][C] Epidermal growth factor receptor, protein kinase B/akt, and glioma response to Erlotinib

DA HAAS-KOGAN, MD PRADOS… - Journal of the …, 2005 - pascal-francis.inist.fr
Epidermal growth factor receptor, protein kinase B/akt, and glioma response to Erlotinib CNRS
Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search …
[PDF] psu.edu

[PDF][PDF] Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib

DA Haas-Kogan, MD Prados, T Tihan… - Journal of the National …, 2005 - Citeseer
Background: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib
(also known as Tarceva or OSI-774) has shown promising response rates in malignant …

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.

DA Haas-Kogan, MD Prados, T Tihan… - Journal of the …, 2005 - europepmc.org
Background The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib
(also known as Tarceva or OSI-774) has shown promising response rates in malignant …
[PDF] academia.edu

[PDF][PDF] Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib

DA Haas-Kogan, MD Prados, T Tihan… - Journal of the National …, 2005 - academia.edu
Background: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib
(also known as Tarceva or OSI-774) has shown promising response rates in malignant …